US › Healthcare

Neuphoria Therapeutics Inc (NEUP)

US · Healthcare · Biotechnology

$3.89-1.02%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-505,063
Profit YoY
-104.5%
EPS
$-0.09
EPS estimate
$-0.56

EPS came in at -0.09 against a street estimate of -0.56 — a beat of 83.9%.

Key statistics

Market cap
$21.2M
Forward P/E
0.0
P/B
0.72
Book value
$5.47
EPS (TTM)
$-7.90
52-week high
$21.40
52-week low
$3.19
50-day MA
$4.22
200-day MA
$4.66

Analyst view

Analysts rate Neuphoria Therapeutics Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $7.00.

Shareholding

Insiders
7.70%
Institutions
55.03%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP16.20%
AdvisorShares Investments, LLC2.87%
Shay Capital LLC2.79%
Balyasny Asset Management LLC2.63%
Vanguard Capital Management, LLC1.82%
Squadron Capital Management LLC1.42%
Geode Capital Management, LLC0.96%
Ikarian Capital, LLC0.88%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neuphoria Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.